Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation

1986 ◽  
Vol 31 (4) ◽  
pp. 469-472 ◽  
Author(s):  
P. D. Fowler ◽  
P. T. Dawes ◽  
V. A. John ◽  
P. A. Shotton
Keyword(s):  
Synovial Fluid ◽  
Slow Release ◽  
Diclofenac Sodium ◽  
Daily Administration ◽  
Release Formulation ◽  
Once Daily ◽  
Hydroxylated Metabolites ◽  
Slow Release Formulation

Experiences with Metoprolol Durules®, A Slow-Release Formulation in Hypertension

1980 ◽  
Vol 8 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Jaakko Tuomilehto ◽  
Aulikki Nissinen
Keyword(s):  
Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Moderate Hypertension ◽  
Antihypertensive Effect ◽  
Slow Release ◽  
Final Dose ◽  
Release Formulation ◽  
Once Daily ◽  
Slow Release Formulation ◽  
The Mean

The antihypertensive effect and the tolerability of metoprolol Durules® have been studied in fifty-five patients with mild to moderate hypertension. The patients' diastolic blood pressure was ≥95 mm Hg in order to qualify for entry. Thirty-seven out of fifty-three patients completing the study (70%) were treated with metoprolol Durules® monotherapy throughout the study. The mean blood pressure was reduced from 153/101 to 138/92 mm Hg after metoprolol Durules® compared to placebo (p < 0.001). Twenty-seven patients received one Durules® daily and ten patients received two Durules® daily as the final dose. Of the sixteen patients not responding on metoprolol Durules®, six patients achieved satisfactory control, i.e. a diastolic blood pressure below 95 mm Hg, when given 200 mg metoprolol + 25 mg hydrochlorothiazide (HCT). The results indicate that most patients with, mild or moderate hypertension can be controlled with metoprolol Durules® monotherapy given once daily. The addition of HCT gives a significant benefit in moderate hypertension, where metoprolol monotherapy is not sufficient.

Comparison of a Slow-Release Formulation of Oxprenolol with Conventional Oxprenolol in the Treatment of Hypertension

1976 ◽  
Vol 51 (s3) ◽  
pp. 559s-561s
Author(s):  
K. P. O'brien ◽  
E. J. W. Stephens
Keyword(s):  
Blood Pressure ◽  
Patient Compliance ◽  
Slow Release ◽  
Severe Hypertension ◽  
Total Daily Dose ◽  
Release Formulation ◽  
Once Daily ◽  
Slow Release Formulation ◽  
Daily Dose ◽  
Treatment Of Hypertension

1. Patients with moderate to severe hypertension were studied during a 12 weeks period, while taking a slow-release formulation of oxprenolol once daily, in a dose equal to their previous total daily dose of oxprenolol given in divided doses. 2. There were no significant differences between blood pressure at the beginning and end of the 12 weeks period. 3. Once-daily dosage offers advantages of patient compliance.

Experience with Once-Daily and Twice-Daily Slow-Release Frusemide in Hypertension

1982 ◽  
Vol 10 (4) ◽  
pp. 199-203 ◽  
Author(s):  
T A Vadász ◽  
Dev R Chadha
Keyword(s):  
Moderate Hypertension ◽  
Slow Release ◽  
Daily Administration ◽  
Double Blind ◽  
Release Formulation ◽  
Once Daily ◽  
Salt Diet ◽  
Low Salt ◽  
Blind Comparison ◽  
Dose Levels

Out of thirty-six patients with mild to moderate hypertension twenty-six patients completed a double-blind comparison of slow-release frusemide at two dose levels, and placebo. The two groups differed in their age pattern, baseline level of blood pressure and response to a low-salt diet during the wash-out/run-in period. Despite the lack of comparability of the two groups, firm clinical inferences could be drawn from the study. Seven of the eighteen placebo patients had to be withdrawn from further participation because of deterioration in their hypertension: in contrast, fifteen of the eighteen frusemide patients showed an anti-hypertensive response and none was withdrawn because of lack of effect. Twice-daily administration of the slow-release formulation, however, produced an unacceptable level of such side-effects as nocturia, nausea and vomiting. Once-daily administration of the preparation is therefore preferred.

THEOPHYLLINE ATTENUATION OF AIRWAY RESPONSES TO ALLERGEN: COMPARISON WITH CROMOLYN METERED-DOSE INHALER

PEDIATRICS ◽  
1996 ◽  
Vol 98 (2) ◽  
pp. 341-341
Author(s):  
Robert A. Wood
Keyword(s):  
Slow Release ◽  
Dose Inhaler ◽  
Metered Dose Inhaler ◽  
Release Formulation ◽  
Once Daily ◽  
Slow Release Formulation ◽  
Metered Dose ◽  
Airway Responses

Theophylline administered as a once daily slow-release formulation was as effective as cromolyn delivered by an MDI in attenuating airway responses to inhaled allergen.

scholarly journals Mesalazine (5-aminosalicylic acid) induced chronic hepatitis

Gut ◽  
1999 ◽  
Vol 44 (6) ◽  
pp. 886-888 ◽  
Author(s):  
P Deltenre ◽  
A Berson ◽  
P Marcellin ◽  
C Degott ◽  
M Biour ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Side Effects ◽  
Adverse Effects ◽  
Liver Dysfunction ◽  
Liver Enzymes ◽  
Slow Release ◽  
Aminosalicylic Acid ◽  
Safe Alternative ◽  
Release Formulation ◽  
Slow Release Formulation

BACKGROUNDTreatment of ulcerative colitis or Crohn’s disease with sulphasalazine causes several adverse effects, including hepatitis. Sulphasalazine is cleaved by colonic bacteria into 5-aminosalicylic acid and sulphapyridine. Received wisdom was that 5-aminosalicylic acid was topically active, whereas sulphapyridine was absorbed and caused immunoallergic side effects. Mesalazine, a slow release formulation of 5-aminosalicylic acid, was expected to be a safe alternative. However, several cases of acute hepatitis have been reported.CASE REPORTA 65 year old man had increased liver enzymes, anti-nuclear and anti-smooth muscle autoantibodies and IgG levels, and lesions of chronic hepatitis after 21 months of mesalazine treatment. Although liver dysfunction had been identified eight months earlier, simvastatin rather than mesalazine had been withdrawn, without any improvement. In contrast, liver enzyme and IgG levels became normal and autoantibodies disappeared after discontinuation of mesalazine administration.CONCLUSIONContrary to initial expectations, mesalazine can cause most of the sulphasalazine induced adverse effects, and hepatic side effects may be almost as frequent. When liver dysfunction occurs, mesalazine administration should be discontinued to avoid the development of chronic hepatitis and liver fibrosis.

Pharmacokinetics of a Slow-Release Formulation of Soybean Isoflavones in Healthy Postmenopausal Women

2005 ◽  
Vol 53 (6) ◽  
pp. 1938-1944 ◽  
Author(s):  
Kenneth D. R. Setchell ◽  
Amnon Brzezinski ◽  
Nadine M. Brown ◽  
Pankaj B. Desai ◽  
Murad Melhem ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Slow Release ◽  
Release Formulation ◽  
Soybean Isoflavones ◽  
Slow Release Formulation

Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus andper os slow-release formulation

1991 ◽  
Vol 36 (12) ◽  
pp. 1735-1740 ◽  
Author(s):  
S. Bondesen ◽  
J. Hegnh�j ◽  
F. Larsen ◽  
S. Honor� Hansen ◽  
C. P. Hansen ◽  
...  
Keyword(s):  
Slow Release ◽  
Intravenous Bolus ◽  
Aminosalicylic Acid ◽  
Release Formulation ◽  
Slow Release Formulation
Sign in / Sign up

Export Citation Format

Share Document